A Randomized, Multicenter, Phase III Trial of Trabectedin (Yondelis) Versus Doxorubicin-Based Chemotherapy as First-Line Therapy in Patients With Translocation-Related Sarcomas (TRS).

Trial Profile

A Randomized, Multicenter, Phase III Trial of Trabectedin (Yondelis) Versus Doxorubicin-Based Chemotherapy as First-Line Therapy in Patients With Translocation-Related Sarcomas (TRS).

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Sep 2015

At a glance

  • Drugs Trabectedin (Primary) ; Doxorubicin; Ifosfamide
  • Indications Soft tissue sarcoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 21 Nov 2014 Post hoc analysis of BRCA1 protein expression influence on trabectedin and doxorubicin efficacy presented at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
    • 07 Feb 2014 Results published in the European Journal of Cancer.
    • 04 Jun 2013 Interim results presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top